Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer

Mohammed Aldakkak(Medical College of Wisconsin), Susan Tsai(The Ohio State University Wexner Medical Center), Kathleen K. Christians(Medical College of Wisconsin), Ashley N. Krepline(Medical College of Wisconsin), Douglas B. Evans(The University of Texas MD Anderson Cancer Center), Fabian M. Johnston(Medical College of Wisconsin), Bradley A. Erickson(Medical College of Wisconsin), Ben George(Medical College of Wisconsin), Paul S. Ritch(Medical College of Wisconsin)
HPB
August 10, 2015
10.1111/hpb.12448
Cited by 69

Related Papers

Recommendations from gynaecological (GYN) GEC ESTRO working group (II): Concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy—3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology
|Radiotherapy and Oncology|2006|1.6k
Consensus Guidelines for Delineation of Clinical Target Volume for Intensity-Modulated Pelvic Radiotherapy for the Definitive Treatment of Cervix Cancer
|International Journal of Radiation Oncology*Biology*Physics|2010|458
Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis
|HPB|2011|413
Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models
|BMC Cancer|2018|391
Population-Based Study of Islet Cell Carcinoma
|Annals of Surgical Oncology|2007|338